UBS confirms its Neutral recommendation on the stock, with an unchanged target price of E108. The analyst believes that the NAPOLI-3 data are in line with his expectations.

' The detailed NAPOLI-3 data presented at ASCO GI were in line with our expectations. We continue to expect first-line use and our forecast for Onyvide remains above consensus' says UBS.

Ipsen presented the NAPOLI 3 phase III trial on the Onivyde® regimen, which showed positive survival results in previously untreated metastatic pancreatic ductal adenocarcinoma.

' These results represent a potential breakthrough in an aggressive and difficult-to-treat cancer', said the group.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.